EUVIMEDEUVIMED entdecken
Open Access

Projected impact of anti‐obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity

Mary Ellen Vajravelu iD, Patricia Y Chu, David A Frank, Maya I Ragavan, Ravy K Vajravelu

Pediatric Obesity · 2024

DOI: 10.1111/ijpo.13103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Obesity, 2024. Verfasst von Mary Ellen Vajravelu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, Diabetes, and Metabolism, University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh…. Hauptthemen laut MEDLINE: Ethnicity, Health Status Disparities, Pediatric Obesity. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paediatric obesity disproportionately impacts individuals from minoritized racial and ethnic backgrounds. Recent guidelines support use of anti‐obesity pharmacotherapy for adolescents with obesity, but the potential impact on disparities in obesity prevalence has not been evaluated.

Objectives

To model changes in obesity prevalence with increasing utilization of anti‐obesity pharmacotherapy among adolescents.

Methods

Data representative of American adolescents ages 12–17 years were obtained from the National Health and Nutrition Examination Survey, cycles 2011 through pre‐pandemic 2020. A body mass index (BMI) reduction of 16.7% was applied to each participant based on clinical trial results of weekly subcutaneous semaglutide 2.4 mg among adolescents. Utilization disparities were based on utilization of the same medication class among adults. Obesity prevalence was calculated assuming utilization of 10%–100%, stratified by race and ethnicity.

Results

Among 4442 adolescents representing 26 247 384 American adolescents, projected overall obesity prevalence decreased from 22.2% to 8.4% with 100% utilization. However, disparities increased relative to Non‐Hispanic White youth, with prevalence among Non‐Hispanic Black and Mexican American youth ranging from 40%–60% higher to 90%–120% higher, respectively.

Conclusions

Increasing utilization of anti‐obesity pharmacotherapy may widen relative disparities in obesity, particularly if utilization is unequal. Advocacy for equitable access is needed to minimize worsening of obesity‐related disparities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EthnicityHealth Status DisparitiesPediatric ObesityAdolescentChildHumansBody Mass IndexNutrition SurveysUnited StatesWeight LossClinical Trials as Topic

Stichwörter der Autor:innen

adolescentbody mass indexequityobesitypharmacotherapy

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology, Diabetes, and Metabolism, University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Division of Endocrinology and Diabetes, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
  • Division of General Academic Pediatrics, University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Mary Ellen Vajravelu

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Vajravelu, M. E., Chu, P. Y., Frank, D. A., Ragavan, M. I., & Vajravelu, R. K. (2024). Projected impact of anti‐obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity. Pediatric Obesity. https://doi.org/10.1111/ijpo.13103

Vancouver

Vajravelu ME, Chu PY, Frank DA, Ragavan MI, Vajravelu RK. Projected impact of anti‐obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity. Pediatric Obesity. 2024. doi:10.1111/ijpo.13103

BibTeX
@article{Vajravelu2024,
  author = {Vajravelu, Mary Ellen and Chu, Patricia Y and Frank, David A and Ragavan, Maya I and Vajravelu, Ravy K},
  title = {Projected impact of anti‐obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity},
  journal = {Pediatric Obesity},
  year = {2024},
  doi = {10.1111/ijpo.13103}
}
Kostenlos starten →